A robust early immunologic response significantly reduced the risk for virus-related non-AIDS–defining cancers, underscoring the need for effective ART, particularly among patients with poor immunologic status.
Increased risk of HSILs detected by random biopsy was associated with greater number of HSILs detected by standard biopsy, whereas oncogenic HPV infection, provider/venue were associated with increased risk of HSILs detected by random or standard biopsy.
High incidence of early deaths in patients initiating first-line ART during antifungal induction therapy for CM vs deferring ART until ≥ 5 weeks after CM diagnosis.
A 4-month regimen with twice-weekly rifapentine 900 mg plus moxifloxacin in the continuation phase was safe but demonstrated inferior efficacy compared with an isoniazid-containing control regimen.
In this small dose-finding study, rifampin doses up to 35 mg/kg were safe, well tolerated, and more active than the currently used 10-mg/kg dose in patients with newly diagnosed TB.
Nearly 90% of HCV treatment-naive patients and previous relapsers met the criteria for response-guided therapy and received a shortened treatment duration, of whom 75% attained SVR12.
SVR8 attained by 93% to 96% of patients in the 12-week arms; both regimens safe and generally well tolerated, with anemia and grade 3/4 bilirubin increases in the RBV-containing treatment arms only.
In a single-center pilot study, a 12-week course of telaprevir and peginterferon/ribavirin in MSM with acute genotype 1 HCV infection was associated with an SVR24 rate of 79%.
Rates of virologic suppression in both plasma and cerebrospinal fluid were also lower in patients who received CNS-targeted vs non-CNS–targeted therapy, possibly due to lower CD4+ cell count nadir and higher prevalence of HCV coinfection in patients who received CNS-targeted therapy.
In interim analysis, 82% of HCV treatment–naive patients and 91% of previous relapsers coinfected with HIV attained HCV RNA below lower limit of quantitation with faldaprevir plus peginterferon/ribavirin at Week 12 of therapy.
Non-AIDS–defining cancer diagnoses occurred approximately 7 months earlier in HIV-infected adults vs HIV-uninfected adults.
Modelling data suggest relative risk for CVD or CHD increased slightly faster in HIV-infected patients vs general population controls, but relative risk for MI was not increased.
Preferential HCV reinfection of HIV-infected MSM with genotypes other than the primary infection suggests original infection confers partial immunity to similar genotype.
The use of interventions post-MI, including CVD risk-lowering medications and invasive cardiovascular procedures, has increased since 1999 for HIV-infected patients.
Greater mortality risk reduction was observed with exposure to atorvastatin and rosuvastatin—considered potent statins—as compared with all statins.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.